March 2018

Mastering mAb Manufacture

Experts share their tips and tricks for enhancing the production of monoclonal antiboides

Compliance and Collaboration

Regulatory changes have brought gradual improvements to pharma logistics, but unless the industry focuses on setting up compliant supply chains with reliable partners – rather than cost alone – wastage will continue to be a problem.

Air or Sea: the Verdict

Logistical Nightmares

We’ve heard some of the shortcomings of pharma logistics, but what happens when things really go wrong?

Need for Speed

Stan Wraight, Senior Executive Director of Strategic Aviation Solutions International and Jan Krems, President of United Cargo, argue that airfreight is the only choice, if speed is your priority.

Is the Tide Turning?

Mark Edwards, former Global Freight and Compliance Manager for Actavis and Managing Director of supply chain consultancy Modalis, argues that pharma companies should transport the majority of their products via sea.

Pharma Logistics 101: Up, Up and Away?

Alan Kennedy is the founder and executive director of Pharma TEAM-UP, a not-for-profit organization seeking to get pharma companies working together on logistics. Here, Kennedy gives an introduction to the sector and discusses where improvements could be made.

And The Winner Is…

In December 2017, 15 top technologies for drug development were selected for The Medicine Maker 2017 Innovation Awards. But which is the most groundbreaking? We asked for your opinion on the matter by asking you to vote for your top technology – and vote you did in earnest! We received thousands of votes from all over the world, but the results are finally in.

How to Beat the Bottleneck

As the accelerating number of monoclonal antibodies on the market continues to drive higher upstream titers, chromatography resin suppliers must continually strive to improve productivity, quality and overall process economy.

Pharma Logistics: Up in the Air or in Deep Water?

Tens of billions of dollars’ worth of (bio)pharmaceuticals are scrapped every year because of logistical hitches. What can be done to improve the situation? And which mode of transport – air or sea – should companies choose?

Easy as eCTD?

Deadlines for mandatory eCTD transitioning are approaching – and companies need to understand how to prepare a compliant submission.

Training the Workforce of the Future

Students have access to a vast knowledge base at university, but are they learning the skills required for a career in biopharma manufacturing? Jefferson and NIBRT unite to better equip the workers of tomorrow.

No Better Time to Be Humble

Sitting Down With... Bruno Sepodes, Professor of Pharmacology and Pharmacotherapy, University of Lisbon, Portugal, and Chair of the EMA Committee of Orphan Medicinal Products (COMP).

Trials of a Medicine Maker

Why embracing single use could help you hedge your bets

All About the Box

Patient adherence is a known issue, but what role does packaging play?

Through the Looking Glass

There is a shocking lack of attention given to racemization in drug discovery, despite it having huge implications on the efficacy – and safety – of drugs. We hope the tool we have developed will be the first step towards change.

Raising the Biosimilar Banner

FDA Commissioner Scott Gottlieb wants more biosimilars on the US market

Will Irish Eyes Keep Smiling?

“Brexit and Trump” were the talk of Dublin town at the 2018 Biopharma Ambition conference

Towards Transparency

Health Technology Assessments are a way of life for the pharma industry, but are all HTAs equal?

Hurt Blocker

Researchers develop a new way to tackle pain: inhibition of RNA-protein interactions

Ancient Herbs with Modern Promise?

Traditional Chinese medicine is viewed with suspicion by mainstream healthcare, but a new collaboration aims to put ancient ingredients to the test

First in Class

Pharma steals the two top spots in a ranking of the best online corporate communications

Calling Time on Bad Behavior

The pharma industry is no stranger to the issue of sexual harassment, but companies are now taking a more public stance on the matter